

Article

## Nickel-Catalyzed Reductive Cycloisomerization of Enynes with CO<sub>2</sub>

Justin Blaise Diccianni, Tyler Heitmann, and Tianning Diao

*J. Org. Chem.*, **Just Accepted Manuscript** • DOI: 10.1021/acs.joc.7b01034 • Publication Date (Web): 14 Jun 2017

Downloaded from <http://pubs.acs.org> on June 16, 2017

### Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



ACS Publications

# Nickel-Catalyzed Reductive Cycloisomerization of Enynes with CO<sub>2</sub>

Justin B. Diccianni, Tyler Heitmann, and Tianning Diao\*

Department of Chemistry, New York University, 100 Washington Square East

New York, NY 10003

E-Mail: [diao@nyu.edu](mailto:diao@nyu.edu)

## ABSTRACT

Carboxylate groups are ubiquitous in bioactive molecules. The syntheses of carboxylates from petroleum feedstock require a series of oxidation reactions. CO<sub>2</sub> represents a cheap and sustainable, pre-oxidized C1 source. Here, we describe a simple, selective, and mild procedure for the construction of (hetero)cyclic  $\alpha,\beta$ -unsaturated carboxylic acids from 1,6- and 1,7-enynes and CO<sub>2</sub>. Terminal 1,7-enynes and sterically hindered alkenes experience a unique change in regioselectivity and form unconjugated carboxylic acids. Mechanistic studies of the reductive cyclization suggest a hydride insertion pathway, explaining the change in regioselectivity caused by steric effects and distinguishing this work from previous reactions involving CO<sub>2</sub>.

## I. Introduction

The vast majority of chemicals are derived from petroleum products via a series of oxidation reactions to increase the oxidation state of carbon and install functional groups. Carbon dioxide represents a sustainable, inexpensive, and clean C1 source, in which the carbon center is already highly oxidized.<sup>1</sup> The advantages of CO<sub>2</sub> as a chemical feedstock underlie recent efforts to develop catalytic methods of incorporating CO<sub>2</sub> into organic molecules.<sup>2</sup> In particular,

functionalization reactions of alkenes and alkynes have provided new synthetic tools for the sustainable construction of molecules.<sup>3</sup>

Cyclic molecules with  $\alpha,\beta$ -unsaturated carbonyl functional groups are ubiquitous in bioactive molecules and synthetic intermediates.<sup>4</sup> In light of the recent advances in the field of Ni catalyzed reductive functionalization of alkenes and alkynes,<sup>5</sup> including work by Martin, Ma, and others, we sought to extend the scope of these reactions to the preparation of  $\alpha,\beta$ -unsaturated cyclic compounds from CO<sub>2</sub>. Here, we report a Ni-catalyzed reductive cycloisomerization of enynes<sup>6</sup> that couples CO<sub>2</sub> to form  $\alpha,\beta$ -unsaturated carboxylic acids. The simple and mild conditions provide high yields of a broad scope of cyclic and heterocyclic carboxylic acids. In addition, we have conducted mechanistic studies and evaluated possible pathways, including ones invoked in previous CO<sub>2</sub> coupling reactions. Our studies suggest that the reaction proceeds via a classic hydride insertion pathway, which is distinct from previous cyclization reactions to incorporate CO<sub>2</sub>.<sup>3</sup>

## II. Results

We initiated our investigation using malonate derived enyne **1a** as a model substrate and evaluated various conditions for the reductive cycloisomerization with CO<sub>2</sub> (Table 1). Mori and coworkers utilized Ni(cod)<sub>2</sub> and PPh<sub>3</sub> to catalyze the cyclization of bis-dienes with CO<sub>2</sub>.<sup>3b</sup> This catalyst system exhibits no reactivity in the cyclization of **1a** in the presence of Et<sub>2</sub>Zn as the reductant (Table 1, entry 1). Replacing PPh<sub>3</sub> with 1,3-bis-(2,6-diisopropylphenyl)imidazol-2-ylidene (IPr) resulted in the formation of the desired cyclic  $\alpha,\beta$ -unsaturated acid **2a** in 81% yield (entry 2). The incorporation of CO<sub>2</sub> into the alkyne is highly selectively, exclusively forming the Z-isomer. The use of NiCl<sub>2</sub>(DME) (DME = dimethoxyethane) as the Ni precursor generated **2a** in a lower yield (entry 3). Louie and coworkers discovered that the pre-generated Ni(IPr)<sub>2</sub>

catalyst outperforms the mixture of Ni(cod)<sub>2</sub> and IPr in their [2+2+2] cycloaddition reactions.<sup>3a</sup> We prepared Ni(IPr)<sub>2</sub> via an optimized literature procedure,<sup>7</sup> and indeed Ni(IPr)<sub>2</sub> was superior to the mixture of Ni(cod)<sub>2</sub> and IPr, giving **2a** in 99% yield (entry 4). We then continued to investigate the stereo and electronic effects of the NHC ligands. Increasing the electron-donating ability of the carbene and decreasing its steric protection led to reduced yields (entries 5-7). We evaluated a variety of reductants as a replacement for Et<sub>2</sub>Zn, including EtZnCl, AlEt<sub>3</sub>, and Et<sub>3</sub>SiH, but they failed to produce the product. Ultimately, the optimal conditions for the cyclization were comprised of Ni(IPr)<sub>2</sub> as the catalysts and Et<sub>2</sub>Zn as the reductant.

**Table 1. Development of the Conditions for the Cycloisomerization of Enyne 1a with CO<sub>2</sub><sup>a</sup>**

IPr:	Entry	Catalyst	Yield (%) <sup>b</sup>
	1	Ni(cod) <sub>2</sub> /PPh <sub>3</sub> <sup>c</sup>	0
	2	Ni(cod) <sub>2</sub> /IPr <sup>c</sup>	81
SIPr:	3	NiCl <sub>2</sub> (DME)/IPr <sup>c</sup>	40
	4	<b>Ni(IPr)<sub>2</sub></b>	<b>99</b>
	5	Ni(SIPr) <sub>2</sub>	42
IMes/SIMes:	6	Ni(IMes) <sub>2</sub>	11
	7	Ni(SIMes) <sub>2</sub>	10


<sup>a</sup> Conditions: **1a** (0.05 mmol), Ni(IPr)<sub>2</sub> (2 mol%), ZnEt<sub>2</sub> (0.15 mmol), THF (1 mL), CO<sub>2</sub> (1 atm), 12 h at 23 °C. <sup>b</sup> NMR yields using TMS as the internal standard. <sup>c</sup> 4 mol % ligand.


We explored the scope of the reductive cycloisomerization with 1 atm of CO<sub>2</sub> (Table 2). Methyl and benzyl malonate derived substrates underwent straightforward cyclization to afford the cyclic α,β-unsaturated acids **2a** and **2b** in high yields. Terminal alkyne **1c** proceeded to generate the 5-membered product **2c** in 64% yield. Aromatic alkyne **1d** gave acid **2d** in 60% yield. Cyclization of 1,7-enyne **1e** gave rise to the six-membered product **2e** in 58% yield.

Unsubstituted 1,6-enyne **1f** lacked reactivity, suggesting the Thorpe-Ingold effect plays a crucial role in facilitating the cyclization. In addition, sterically hindered olefins, such as geminal disubstituted substrate **1g**, exhibited no reactivity.

The reaction conditions tolerate heteroatoms, giving rise to a variety of piperidine, pyrrolidine, and furan derivatives (**2h-2q**). We used single crystal X-ray diffraction to confirm the structure and the stereochemistry of **2j**.  $\alpha$ -Phenyl substituted tosylamide **2l** was formed as a mixture of *cis* and *trans*-diastereomers in a 1:3 ratio, while  $\alpha$ -methyl substituted tosylamide **2m** was formed as a 1:1 mixture of diastereomers. We assigned the diastereomers via NOESY experiments. The tosyl- protecting group of the amine substrates could be substituted by benzoyl- and Boc groups, giving rise to **2n** and **2o** in 74% and 57% yields, respectively. The use of free amines, however, did not result in any product formation. Allyl- propargyl ethers underwent cyclization to generate carboxylic acids **2p** and **2q** in good yields.

**Table 2. Scope of the Reductive Cycloisomerization with CO<sub>2</sub> Incorporated to Alkynes<sup>a</sup>**












<sup>a</sup> Conditions: Enyne = 0.5 mmol. Isolated yields. <sup>b</sup> 4% Ni(IPr)<sub>2</sub>. <sup>c</sup> Crude product treated with TMSCHN<sub>2</sub> and isolated as methyl ester.

When we evaluated terminal 1,7-enynes, we observed a change in the regioselectivity of the CO<sub>2</sub> incorporation from the alkynes to the alkenes (Scheme 1). Allyl-homopropargyl and homoallyl-propargyl substrates, **3a-3c** and **3d-3f**, respectively, underwent cyclization to form carboxylic acids **4a-4f**. In contrast with the regioselectivity observed for 1,6-enynes **2a-2q**, 1,7-enynes **3a-3f**, bearing terminal alkynes, incorporated CO<sub>2</sub> onto the olefin. This reaction tolerated *N*- and *O*-heteroatoms and afforded piperidine and tetrahydropyran derivatives. In addition, introducing a phenyl substituent on the olefin led to the same change in regioselectivity of the CO<sub>2</sub> incorporation to afford saturated carboxylate **4g** as a 10:1 mixture of diastereomers. The addition of the hydride to the alkyne was exclusively *cis* to the newly formed C–C bond in **4g**.

### Scheme 1. Scope of Reductive Cyclization with CO<sub>2</sub> Incorporated to Alkenes



We next turned our focus to probing the mechanism. In the presence of 0.5 equivalents of  $\text{CO}_2$ , relative to the enyne substrate, the cyclization reaction of **1d** proceeded under standard conditions to form the carboxylation product **2d** accompanied by a reductive cycloisomerization product **5d** (eq 1).<sup>8</sup> Cyclization of **1a** with  $\text{ZnEt}_2$ - $d_{10}$  formed carboxylic acid **2a-D** in 85% isolated yield (Scheme 2).  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra established that a single deuterium atom was incorporated into the methyl group in 97% efficiency. The use of  $\text{ZnEt}_2$ - $d_{10}$  in the cyclization of **3b** led to >99% deuterium incorporation into the terminal olefin of **4b**. The diastereoselectivity of the deuterium incorporation is high with the deuterium *cis*- to the newly formed C–C bond, and no H/D scrambling observed. We conducted kinetic studies for the carboxylation of **1a** using NMR analysis. The reaction time course fits to a first order kinetic model (Figure 1A).<sup>9</sup> Comparing the reaction rates with  $\text{ZnEt}_2$  and  $\text{ZnEt}_2$ - $d_{10}$  revealed a kinetic isotope effect of  $0.911 \pm 0.1$  (Figure 1B).

Scheme 2. Cyclization of 1a and 3d with  $\text{ZnEt}_2\text{-}d_{10}$ 



**Figure 1.** Kinetic profiles of reductive cyclization of **1a** with Et<sub>2</sub>Zn (A) and Et<sub>2</sub>Zn-*d*<sub>10</sub> (B). Conditions: [**1a**]<sub>0</sub> = 0.021 M, [Et<sub>2</sub>Zn]<sub>0</sub> = 0.050 mM, CO<sub>2</sub> = 1 atm, solvent = THF, temperature = 22 °C, internal standard = tetramethylsilane.

We conducted spectroscopic studies of the catalytic reaction and a series of stoichiometric experiments to elucidate the nature of the Ni catalyst. The EPR spectrum of a reaction mixture of **2a** under standard conditions frozen to 10 K showed no signal. When we monitored the stoichiometric reaction of Ni(IPr)<sub>2</sub> with **1a** in the presence of ZnEt<sub>2</sub> and CO<sub>2</sub> by in-situ <sup>1</sup>H NMR spectroscopy, we observed a diamagnetic Ni species. When CO<sub>2</sub> and/or Et<sub>2</sub>Zn were excluded from the reaction, no conversion of **1a** was detected. Mixing stoichiometric Ni(IPr)<sub>2</sub> and enyne **1a** resulted in no reaction. When CO<sub>2</sub> was introduced to the dark purple solution of Ni(IPr)<sub>2</sub>, the color immediately changed to yellow. Upon addition of enyne **1a**, the <sup>1</sup>H NMR spectrum of the mixture exhibits a new Ni species but no conversion of **1a** (Figure S1). Introducing Et<sub>2</sub>Zn to the reaction mixture resulted in formation of **2a**.


### III. Discussion

The experiments presented above allow us to evaluate possible pathways for the reductive cyclization. The formation of reductive cycloisomerization product **5d** in the presence of insufficient CO<sub>2</sub> (eq 1) suggests that cyclization occurs prior to the incorporation of CO<sub>2</sub>. Deuterium labeling studies with Et<sub>2</sub>Zn-*d*<sub>10</sub> (Scheme 2) reveal that the hydrogen atom incorporated into the product originates from Et<sub>2</sub>Zn. The lack of H/D scrambling suggests that hydride insertion is irreversible. The negligible KIE with Et<sub>2</sub>Zn-*d*<sub>10</sub> implies that steps involving the cleavage of the C–H bonds of Et<sub>2</sub>Zn and Ni–hydride are fast. Analysis of the reaction mixture by EPR spectroscopy excludes Ni(I) or Ni(III) species as the catalyst resting state. <sup>1</sup>H NMR

studies of the catalyst activation provide circumstantial evidence for diamagnetic intermediates involved in catalysis.

Our stoichiometric experiments establish that  $\text{Ni}(\text{IPr})_2$  alone does not react with the enyne substrate. Both  $\text{CO}_2$  and  $\text{Et}_2\text{Zn}$  are crucial to activate the Ni catalyst. The reaction of  $\text{CO}_2$  with  $\text{Ni}(0)$  results in an immediate color change, possibly forming side-on adduct **6**, as is known for  $\text{Ni}(0)$ -phosphine complexes.<sup>10</sup> The enyne substrate **1a**, however, does not react with **6**, evident from stoichiometric studies (Figure S1). Based on previous studies by Dong and coworkers,<sup>11</sup>  $(\text{IPr})_2\text{Ni}(0)\text{-CO}_2$  adduct **6** can transmetallate with  $\text{Et}_2\text{Zn}$  to form intermediate **7** (Scheme 3). Upon release of ethylene,  $\beta$ -H elimination gives rise to  $\text{Ni-H}$  **8**, which enters the catalytic cycle. Alternatively, nucleophilic addition of  $\text{Et}_2\text{Zn}$  to the carbonyl of **6** could form intermediate **9**, followed by  $\beta$ -H elimination to generate  $\text{Ni(II)-H}$  **10**. Consistent with this proposal,  $\text{Ni(II)}$  precursors, such as  $\text{NiCl}_2(\text{DME})$ , are active in catalyzing the reductive cyclization reaction (Table 1, entry 3). We attribute the lower yield of  $\text{NiCl}_2(\text{DME})$  compared with  $\text{Ni}(\text{IPr})_2$  to catalyst decomposition when the coordination of  $\text{IPr}$  to  $\text{NiCl}_2(\text{DME})$  is incomplete.


### Scheme 3. Proposed Activation of the Ni Catalyst by $\text{CO}_2$ and $\text{Et}_2\text{Zn}$



Oxidative cycloaddition of alkenes and alkynes with  $\text{Ni}(0)$  has been invoked in Ni-catalyzed reductive coupling reactions<sup>5f</sup> and early reports in Ni-mediated  $\text{CO}_2$  functionalization.<sup>12</sup> If the reductive cyclization proceeded through this pathway,  $\text{CO}_2$  could undergo nucleophilic attack by the metallocycle intermediate followed by reductive cleavage with  $\text{Et}_2\text{Zn}$  (Scheme 4, Path 1). This pathway is consistent with our observation that cyclization precedes the incorporation of

CO<sub>2</sub>, but is inconsistent with the lack of reactivity between enyne **1a** and Ni(IPr)<sub>2</sub> in stoichiometric studies.<sup>13</sup>

#### Scheme 4. Possible Pathways of Ni-Catalyzed Reductive Cycloisomerization



Louie and coworkers proposed a cycloaddition between CO<sub>2</sub>, Ni(0), and an alkyne.<sup>3a</sup> It is conceivable that a similar reaction could form a metallolactone, which inserts into the alkene and generate the final product (Scheme 4, Path 2). This pathway is inconsistent with cyclization preceding the incorporation of CO<sub>2</sub>, evident from the formation of reductive cyclization product **5d**. In addition, the lack of reactivity between Ni(IPr)<sub>2</sub>, enyne **1a**, and CO<sub>2</sub> in the absence of Et<sub>2</sub>Zn contrasts with Path 2.


In a Ni-catalyzed reductive cyclization of diynes with CO<sub>2</sub>, Ma and coworkers invoked transmetalation between a Ni(0)-alkyne adduct and Et<sub>2</sub>Zn to afford a vinyl-zinc intermediate (Scheme 4, Path 3). Further olefin insertion generates the cyclized product.<sup>3g</sup> The vinyl-Zn intermediate is responsible for the nucleophilic attack on CO<sub>2</sub> to form the carboxylic acid. In the report by Ma, reductive cyclization of the diynes occurs in high yield in the absence of CO<sub>2</sub>.<sup>3g</sup> In

contrast, our reductive cyclization did not produce any cyclized product in the absence of CO<sub>2</sub>. This observation provides circumstantial evidence to rule out Ma's mechanism.

Our mechanistic data are consistent with Path 4. The reaction initiates by the insertion of a Ni(II)–H species into the alkene, followed by subsequent insertion of the alkyne and activation of CO<sub>2</sub>. When terminal 1,7-enyne **3a-f** and 1,6-enyne **3g**, with steric hindrance on alkene, were used as the substrate, the initial insertion of Ni(II)–H favors the more reactive and sterically more accessible alkyne (Path 5).<sup>14</sup> This change of insertion sequence results in the incorporation of CO<sub>2</sub> into the alkene and forms saturated acids **4a-g**. It is noteworthy that the unique change in selectivity with substrates **3a-g** provides further evidence to exclude Paths 2 and 3, which cannot account for the observed steric effect on the change of insertion sequence.

Collectively, we propose the catalytic cycle shown in Scheme 5 to account for our experimental observations. Irreversible, insertion of Ni–H into the alkene, followed by insertion of the alkyne, gives rise to a vinyl–Ni intermediate **11**, which may directly react with CO<sub>2</sub> (Pathway A).<sup>15</sup> Subsequent transmetallation with Et<sub>2</sub>Zn forms a Ni–Et intermediate, which undergoes β-H elimination to regenerate the Ni–H species. Alternatively, the activation of CO<sub>2</sub> could be preceded by transmetallation to Zn, forming a vinylzinc species which ultimately reacts with CO<sub>2</sub> (Pathway B).<sup>3c</sup> Our current data do not distinguish these two pathways, and ongoing research focuses on elucidating the role of Zn salts in activating CO<sub>2</sub>.

### Scheme 5. Proposed Catalytic Cycle



#### IV. Conclusion

In conclusion, we have developed a simple, selective, and mild procedure for constructing (hetero)cyclic  $\alpha,\beta$ -unsaturated carboxylic acids from 1,6- and 1,7-enynes and  $\text{CO}_2$ . Increasing the steric hindrance on alkene or decreasing the steric hindrance on alkyne results in a unique change in the regioselectivity of the carboxylation to afford unconjugated carboxylic acids. Our mechanistic studies suggest a hydride insertion mechanism is operative, which distinguishes this work from previous reactions in incorporating  $\text{CO}_2$ .

#### Experimental

**General Considerations.** All air- and moisture- sensitive manipulations were carried out in a nitrogen-filled glove box. Solvents were dried and deoxygenated by passing through alumina in a solvent purification system.  $\text{Ni}(\text{cod})_2$  was purchased from Strem and used without further purification. Chloroform- $d$ , benzene- $d_6$ , and bromoethane- $d_5$  were purchased from Cambridge Isotope Laboratories. Substrates **1a-g**, **1i-k**, **1o-q**, **3a**, and **3d-f** were synthesized according to literature procedures.<sup>16a-n</sup>

$^1\text{H}$  and  $^{13}\text{C}$  NMR spectra were recorded on Bruker 600, 500, and 400 MHz Avance spectrometers. The chemical shifts ( $\delta$ ) are given in parts per million and referenced to residual solvent peaks or TMS internal standard. The following abbreviations were used to describe

1  
2  
3 multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, sept = septet, m = multiplet, br =  
4 broad. IR spectra were recorded on a Nicolet 6700 FT-IR spectrometer. X-ray crystallographic  
5 data were collected on Bruker AXS SMART APEXII single crystal diffractometer. High-  
6 resolution mass spectra (HRMS) were collected on an Agilent 6224 TOF LC/MS. Reactions  
7 were monitored by thin layer chromatography (TLC) on Merck TLC Silica gel 60 F<sub>254</sub> plates and  
8 compounds were visualized by UV light (254 nm) or KMnO<sub>4</sub> staining. Column chromatography  
9 was performed on Merck Silica gel 60 (0.015-0.040 mm). Carbon dioxide was purchased from  
10 Airgas and was passed through 2 Drierite columns before use. Melting points were measured  
11 using a Mel-Temp apparatus with open glass capillaries.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

24 *Ni(IPr)<sub>2</sub>*. A 20 mL scintillation vial was charged with Ni(cod)<sub>2</sub> (100 mg, 0.36 mmol, 1 equiv)  
25 and 6 mL THF. With stirring, IPr<sup>17</sup> (282 mg, 0.73 mmol, 2 equiv) was added in 6 mL THF. The  
26 solution quickly turned dark brown, then black. After stirring overnight, solvent was removed  
27 under vacuum, the residue was dissolved in 10 mL toluene, and stirring was continued for a  
28 further 12 hours. After repeating the cycle two more times, volatiles were removed under  
29 vacuum and black residue was suspended in pentane (5 mL) and filtered. The solid was washed  
30 with pentane twice and dried under vacuum to give 166 mg (0.20 mmol, 56%) of Ni(IPr)<sub>2</sub> as a  
31 black, microcrystalline solid. The filtrate was stored at -35 °C. After 24 hours, the supernatant  
32 was removed and the solids were dried under vacuum to afford 35 mg (0.04 mmol, 11%) of  
33 Ni(IPr)<sub>2</sub> (67% overall). The solid was stored at -35 °C. Solutions of Ni(IPr)<sub>2</sub> were found to  
34 decompose over several days at room temperature. The spectroscopic data is in agreement with  
35 the previous reports.<sup>18</sup> **<sup>1</sup>H NMR (600 MHz, C<sub>6</sub>D<sub>6</sub>)** δ 7.28 (t, *J* = 7.7 Hz, 4H), 7.08 (d, *J* = 7.7 Hz,  
36 8H), 6.11 (s, 4H), 3.06 (sept, *J* = 6.9 Hz, 8H), 1.25 (d, *J* = 6.9 Hz, 24H), 1.10 (d, *J* = 6.9 Hz,  
37 24H). **<sup>13</sup>C {<sup>1</sup>H} NMR (151 MHz, C<sub>6</sub>D<sub>6</sub>)** δ 193.5, 145.4, 139.3, 123.3, 120.8, 28.3, 24.5, 23.9.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Procedure for Screening Reaction Conditions:** An oven-dried 25 mL bomb flask was charged with the nickel catalyst, ligand, and THF (0.8 mL) in a nitrogen-filled glovebox. The flask was sealed and removed from the glovebox. Under a stream of CO<sub>2</sub>, enyne 1a (0.05 mmol, 1 equiv) was added as a solution in 0.1 mL THF. After addition of the reductant (2.5 equiv), the flask was degassed three times by the freeze-pump-thaw method. The specified amount of CO<sub>2</sub> was then introduced to the flask and the mixture stirred vigorously for 12 hours at the specified temperature. The mixture was cooled in an ice bath, diluted with 2 mL EtOAc, and quenched with 3 mL 1 M HCl. The aqueous phase was extracted with 2 mL EtOAc three times. The combined organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>. Solvent was removed under vacuum. The crude material was dissolved in CDCl<sub>3</sub> (0.6 mL) followed by the addition of TMS internal standard (0.02 mmol from a stock solution in CDCl<sub>3</sub>) and analysis by NMR spectroscopy. All yields were determined by NMR spectroscopy (Table S1).

**General Procedure for Cyclization Reactions in Bomb Flasks (General Procedure A):**

An oven-dried 25 mL bomb flask was charged with Ni(IPr)<sub>2</sub> (2-4%) and THF (0.8 mL) in a glovebox. The flask was sealed and removed from the glovebox. Under a stream of CO<sub>2</sub>, enyne **1a-q** or **3a-g** (0.05 mmol, 1 equiv) was added as a solution in 0.1 mL THF. After the addition of ZnEt<sub>2</sub> (2.5 equiv) in 0.1 mL THF the solution became turbid. The flask was degassed three times by the freeze-pump-thaw method. The flask was filled with one atmosphere of CO<sub>2</sub>. After stirring vigorously for 12 hours the mixture was cooled in an ice bath, diluted with 2 mL EtOAc, and quenched with ~3 mL 1 M HCl (or sat. NH<sub>4</sub>Cl for substrate **1o**). The aqueous phase was extracted 3 x 2 mL EtOAc. The combined organic phase was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The crude material was dissolved in CDCl<sub>3</sub> (0.6 mL) with TMS (0.02 mmol from a

stock solution in  $\text{CDCl}_3$ ) added and analyzed by NMR spectroscopy. The crude material was then purified by chromatography on silica with elution by mixtures of  $\text{CHCl}_3$  and MeOH.

**General Procedure for Cyclization Reactions in Round-Bottom Flasks (RBF) (General Procedure B):** An oven-dried 50 mL RBF was charged with  $\text{Ni}(\text{IPr})_2$  (2-4%) and THF (8 mL) in a glovebox. The flask was sealed with a septum and brought out of the glovebox. The flask was purged with a balloon of  $\text{CO}_2$  until the solution turned yellow. The balloon was refilled and enyne **1a-q** or **3a-g** (0.5 mmol, 1 equiv) was added in 1 mL THF.  $\text{ZnEt}_2$  (2.5 equiv) was added dropwise in 1 mL THF and the solution became turbid. The mixture was stirred vigorously for 12 hours. The  $\text{CO}_2$  balloon was replaced every 4-8 hours due to corrosion of the balloon by  $\text{ZnEt}_2$ . The mixture was cooled in an ice bath, diluted with 10 mL EtOAc, and quenched with ~5 mL 1 M HCl (or sat.  $\text{NH}_4\text{Cl}$  for substrate **1o**). The aqueous phase was extracted with EtOAc three times. The combined organic phase was washed twice with brine and dried over  $\text{Na}_2\text{SO}_4$ . Solvent was removed under vacuum to give the crude products, which were purified by recrystallization (carboxylic acids **2i** and **2j**), conversion to the corresponding methyl ester with  $\text{TMSCHN}_2$  followed by chromatography on silica with hexane/EtOAc (esters **2e**, **2n**, **2q**, and **4g**), or chromatography of the free acids on silica with  $\text{CHCl}_3/\text{MeOH}$  (all other carboxylic acids).

**General Procedure for Methylation of Carboxylic Acids (General Procedure C):** The crude material was dissolved in 3 mL toluene and 2 mL MeOH were added. The solution was cooled in an ice bath and  $\text{TMSCHN}_2$  (3 equiv, 2 M in hexane) was added dropwise. The ice bath was removed and the solution stirred at room temperature for 1 hour. Acetic acid was added dropwise until the yellow color of  $\text{TMSCHN}_2$  faded, then solvent was removed under vacuum. The methyl esters were then purified by column chromatography on silica with elution by hexane and EtOAc.



**Procedure for Kinetic Experiments:** In parallel, several oven-dried 25 mL bomb flasks were charged with Ni(IPr)<sub>2</sub> (0.001 mmol, 0.02 equiv, 0.8 mL THF) from a stock solution in THF, in a glovebox. The flasks were sealed and removed from the glovebox. Under a stream of CO<sub>2</sub>, enyne **1a** (0.05 mmol, 1 equiv) was added from a stock solution in THF (0.1 mL). After the addition of ZnEt<sub>2</sub> or ZnEt<sub>2</sub>-d<sub>10</sub> (2.5 equiv) in 0.1 mL THF from a stock solution, the flask was degassed three times by the freeze-pump-thaw method. The flask was filled with one atmosphere of CO<sub>2</sub>. After stirring vigorously for the specified time the mixture was cooled in an ice bath, diluted with 2 mL EtOAc, and quenched with ~3 mL 1 M HCl. The aqueous phase was extracted 3 x 2 mL EtOAc. The combined organic phase was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The crude material was dissolved in CDCl<sub>3</sub> (0.6 mL) with TMS (0.02 mmol from a stock solution in CDCl<sub>3</sub>) added and analyzed by NMR spectroscopy. Kinetic experiments were repeated twice in order to assure reproducibility.

**Stoichiometric Reaction Between Ni(IPr)<sub>2</sub>, CO<sub>2</sub>, and 1a.** A J-Young NMR tube was charged with a solution of Ni(IPr)<sub>2</sub> (8 mg, 0.009 mmol, 1 equiv) and enyne **1a** (2 mg, 0.009 mmol, 1 equiv) in 0.6 mL C<sub>6</sub>D<sub>6</sub>. The NMR spectrum of this solution showed no reaction even after 2 days at room temperature. The tube was degassed and refilled with CO<sub>2</sub>, causing the solution to turn yellow/orange. The NMR spectrum of this mixture showed Ni(IPr)<sub>2</sub> had been consumed and a new Ni species formed. Enyne **1a** was unreactive with this new Ni species (Figure S1).

**Reaction with Substoichiometric CO<sub>2</sub>:** An oven-dried 25 mL bomb flask was charged with Ni(IPr)<sub>2</sub> (0.005 mmol, 0.02 equiv) and 4 mL THF in a glovebox. The flask was sealed and removed from the glovebox. Under a stream of CO<sub>2</sub>, enyne **1d** (0.25 mmol, 1 equiv) was added in 0.5 mL THF followed by ZnEt<sub>2</sub> (2.5 equiv) in 0.5 mL THF. The flask was degassed three

times by the freeze-pump-thaw method. Using a gas addition bulb and standard Schlenk technique, 0.5 equivalents of CO<sub>2</sub> were condensed into the flask. The mixture was stirred overnight, cooled in an ice bath, and quenched with 1 M HCl. The aqueous phase was extracted with EtOAc three times. The combined organic phase was washed twice with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. Solvent was removed under vacuum to give the crude products (Figure S2), which were purified by chromatography on silica with 100% CHCl<sub>3</sub> → 100:1 CHCl<sub>3</sub>:MeOH to give **2d** (25 mg, 0.075 mmol, 30%) and **5d** (46 mg, 0.16 mmol, 64%) as colorless oils. The spectroscopic data for compound **5d** matches with that reported in the literature.<sup>19</sup>

*(E)*-dimethyl 3-benzylidene-4-methylcyclopentane-1,1-dicarboxylate (**5d**). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.33 (m, 4H), 7.21 (m, 1H), 6.22 (q, *J* = 2.4 Hz, 1H), 3.73 (s, 3H), 3.72 (s, 3H), 3.39 (d, *J* = 17.6 Hz, 1H), 3.21 (dd, *J* = 17.2, 2.8 Hz, 1H), 2.77 (m, 1H), 2.60 (ddd, *J* = 12.8, 7.2, 1.6 Hz, 1H), 1.77 (dd, *J* = 12.4, 11.6 Hz, 1H), 1.22 (d, *J* = 6.4 Hz, 1H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 172.3, 172.2, 146.0, 137.9, 128.3, 126.2, 121.5, 109.7, 59.0, 52.8, 41.5, 39.1, 39.0, 18.3.

*(Z)*-2-(4,4-bis(methoxycarbonyl)-2-methylcyclopentylidene)propanoic acid (**2a**). Following General Procedure B with enyne **1a** and purification of the crude material via column chromatography (100% CHCl<sub>3</sub> → 10:1 CHCl<sub>3</sub>:MeOH) afforded **2a** as a colorless solid in 96% yield (130 mg, 0.48 mmol). Mp 66–68 °C. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 3.75 (s, 3H), 3.71 (s, 3H), 3.59 (m, 1H), 3.28 (d, *J* = 18.3 Hz, 1H), 2.96 (d, *J* = 18.3 Hz, 1H), 2.59 (dd, *J* = 13.5, 8.2 Hz, 1H), 2.17 (dd, *J* = 13.5, 3.5 Hz, 1H), 1.86 (s, 3H), 1.04 (d, *J* = 7.1 Hz, 3H). <sup>13</sup>C {<sup>1</sup>H} NMR (151 MHz, CDCl<sub>3</sub>) δ 173.2, 172.5, 172.2, 162.7, 119.4, 58.1, 53.01, 52.96, 41.8, 40.8, 37.7, 20.5, 16.3. HRMS (ESI-TOF) *m/z*: [(M+H) – H<sub>2</sub>O]<sup>+</sup> Calcd for C<sub>13</sub>H<sub>17</sub>O<sub>5</sub> 253.1071; Found 253.1070. TLC: R<sub>f</sub> = 0.20 (40:1 CHCl<sub>3</sub>:MeOH).

(Z)-2-(4,4-bis((benzyloxy)carbonyl)-2-methylcyclopentylidene)propanoic acid (**2b**).

Following General Procedure B with enyne **1b** and purification of the crude material via column chromatography (100% CHCl<sub>3</sub> → 10:1 CHCl<sub>3</sub>:MeOH) afforded **2b** as a colorless oil in 90% yield (0.45 mmol, 190 mg). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.32 (m, 6H), 7.28 – 7.26 (m, 2H), 7.23 (m, 2H), 5.18-5.10 (m, 4H), 3.60 (br, 1H), 3.30 (d, *J* = 18.2 Hz, 1H), 2.99 (d, *J* = 18.1 Hz, 1H), 2.65 (dd, *J* = 13.5, 8.3 Hz, 1H), 2.17 (dd, *J* = 13.5, 3.8 Hz, 1H), 1.83 (s, 3H), 1.03 (d, *J* = 7.1 Hz, 3H). <sup>13</sup>C {<sup>1</sup>H} NMR (151 MHz, CDCl<sub>3</sub>) δ 172.6, 171.6, 171.3, 162.8, 135.3, 135.2, 128.6, 128.6, 128.4, 128.4, 128.2, 128.0, 119.4, 67.6, 67.4, 58.4, 41.8, 40.7, 37.7, 20.7, 16.4. HRMS (ESI-TOF) *m/z*: [M+H]<sup>+</sup> Calcd for C<sub>25</sub>H<sub>27</sub>O<sub>6</sub> 423.1808; Found 423.1802. TLC: R<sub>f</sub> = 0.64 (10:1 CHCl<sub>3</sub>:MeOH).

(Z)-2-(4,4-bis(methoxycarbonyl)-2-methylcyclopentylidene)acetic acid (**2c**).

Following General Procedure B with enyne **1c** and purification of the crude material via column chromatography (100% CHCl<sub>3</sub> → 10:1 CHCl<sub>3</sub>:MeOH) afforded **2c** as a tan oil in 64% yield (0.32 mmol, 82 mg). This compound slowly isomerizes to the *E* isomer. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 5.78 (s, 1H), 3.76 (s, 3H), 3.72 (s, 3H), 3.54 (q, *J* = 7.0 Hz, 1H), 3.31 (dt, *J* = 17.2, 2.0 Hz, 1H), 2.95 (d, *J* = 17.2 Hz, 1H), 2.73 (ddd, *J* = 13.6, 8.4, 2.0 Hz, 1H), 2.03 (dd, *J* = 13.6, 8.4 Hz, 1H), 1.16 (d, *J* = 7.0 Hz, 3H). <sup>13</sup>C {<sup>1</sup>H} NMR (151 MHz, CDCl<sub>3</sub>) δ 171.9, 171.6, 170.8, 147.4, 123.8, 58.2, 53.02, 52.99, 42.8, 41.6, 36.3, 20.5. HRMS (ESI-TOF) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>12</sub>H<sub>16</sub>O<sub>6</sub>Na 279.0840; Found 279.0858. TLC: R<sub>f</sub> = 0.38 (20:1 CHCl<sub>3</sub>:MeOH).

(Z)-2-(4,4-bis(methoxycarbonyl)-2-methylcyclopentylidene)-2-phenylacetic acid (**2d**).

Following General Procedure B with enyne **1d** and purification of the crude material via column chromatography (100% CHCl<sub>3</sub> → 100:1 CHCl<sub>3</sub>:MeOH) afforded **2d** as a colorless oil in

60% yield (0.30 mmol, 100 mg). **<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)** δ 7.39 – 7.34 (m, 2H), 7.32 – 7.28 (m, 1H), 7.16 (dd, *J* = 8.1, 1.3 Hz, 2H), 3.70 (br s, 4H), 3.66 (s, 3H), 3.05 (dd, *J* = 17.8, 1.9 Hz, 1H), 2.74 – 2.65 (m, 2H), 2.09 (dd, *J* = 13.6, 5.2 Hz, 1H), 1.20 (d, *J* = 7.0 Hz, 3H). **<sup>13</sup>C {<sup>1</sup>H} NMR (151 MHz, CDCl<sub>3</sub>)** δ 172.0, 171.7, 171.3, 165.6, 138.0, 129.2, 128.4, 127.5, 126.5, 58.2, 52.9, 52.9, 41.61, 41.59, 37.1, 20.9. **HRMS (ESI-TOF) *m/z*:** [M+H]<sup>+</sup> Calcd for C<sub>18</sub>H<sub>21</sub>O<sub>6</sub> 333.1338; Found 333.1307. **TLC:** R<sub>f</sub> = 0.48 (10:1 CHCl<sub>3</sub>:MeOH).

*Dimethyl (Z)-3-(1-methoxy-1-oxopropan-2-ylidene)-4-methylcyclohexane-1,1-dicarboxylate (2e).* Following General Procedure B followed by General Procedure C with enyne **1e** and purification of the crude material via column chromatography (10:1 hexane:EtOAc) afforded **2e** as a slightly yellow oil in 58% yield (0.29 mmol, 87 mg) (82% b.r.s.m.). **<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)** δ 3.74 (s, 3H), 3.712 (s, 3H), 3.710 (s, 3H) 3.15 (ddd, *J* = 14.3, 2.1, 1.1 Hz, 1H), 3.13 – 3.07 (m, 1H), 2.44 (dd, *J* = 14.4, 1.4 Hz, 1H), 2.20 (dq, *J* = 13.7, 3.6 Hz, 1H), 2.03 (td, *J* = 13.7, 4.2 Hz, 1H), 1.91 (d, *J* = 1.4 Hz, 3H), 1.68 (tt, *J* = 13.7, 4.2 Hz, 1H), 1.54 (dq, *J* = 14.0, 3.6 Hz, 1H), 1.14 (d, *J* = 7.1 Hz, 3H). **<sup>13</sup>C {<sup>1</sup>H} NMR (151 MHz, CDCl<sub>3</sub>)** δ 172.4, 170.8, 170.7, 144.9, 123.7, 77.4, 56.8, 53.0, 52.6, 51.6, 32.6, 30.0, 26.0, 18.6, 15.5. **HRMS (ESI-TOF) *m/z*:** [M+H]<sup>+</sup> Calcd for C<sub>15</sub>H<sub>23</sub>O<sub>6</sub> 299.1490; Found 299.1496. **TLC:** R<sub>f</sub> = 0.20 (10:1 hexane:EtOAc).

*(E)-2-(3-methyl-1-tosylpiperidin-4-ylidene)-2-(trimethylsilyl)acetic acid (2h).* Following General Procedure B with enyne **1h** and purification of the crude material via column chromatography (100% CHCl<sub>3</sub> → 100:1 CHCl<sub>3</sub>:MeOH) afforded **2h** as a colorless oil in 62% yield (0.31 mmol, 123 mg). **<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)** δ 7.61 (d, *J* = 8.2 Hz, 2H), 7.31 (d, *J* = 8.2 Hz, 2H), 3.91 (dq, *J* = 8.2, 2.6 Hz, 1H), 3.59 (d, *J* = 11.3 Hz, 1H), 2.76 (d, *J* = 6.9 Hz, 1H), 2.64 (dd, *J* = 13.3, 5.3 Hz, 1H), 2.43 (s, 3H), 2.38 – 2.29 (m, 1H), 2.22 – 2.13 (m, 1H), 1.30 (d, *J* = 6.9 Hz, 3H), 1.16 (t, *J* = 7.6 Hz, 1H), 0.17 (s, 9H). **<sup>13</sup>C {<sup>1</sup>H} NMR (151 MHz, CDCl<sub>3</sub>)** δ 176.1,

153.8, 143.7, 133.1, 130.8, 129.7, 127.6, 52.3, 47.2, 36.7, 28.8, 21.5, 18.2, -0.2. **HRMS (ESI-TOF)  $m/z$ :**  $[M+H]^+$  Calcd for  $C_{18}H_{28}NO_4SSi$  382.1508; Found 382.1503. **TLC:**  $R_f$  = 0.33 (10:1  $CHCl_3$ :MeOH).

(*E*)-2-(4-methyl-1-tosylpyrrolidin-3-ylidene)propanoic acid (**2i**). Following General Procedure B with enyne **1i** and purification of the crude material via recrystallization from  $CH_2Cl_2$ /hexane afforded **2i** as an off-white solid in 87% yield (0.44 mmol, 136 mg). Mp 99–101 °C.  **$^1H$  NMR (600 MHz,  $CDCl_3$ )**  $\delta$  7.71 (d,  $J$  = 8.0 Hz, 2H), 7.34 (d,  $J$  = 8.0 Hz, 2H), 4.16 (d,  $J$  = 16.6 Hz, 1H), 3.68 – 3.51 (m, 2H), 3.35 (d,  $J$  = 9.1 Hz, 1H), 2.98 (dd,  $J$  = 9.1, 6.1 Hz, 1H), 2.43 (s, 3H), 1.75 (s, 3H), 1.18 (d,  $J$  = 6.9 Hz, 3H).  **$^{13}C$  { $^1H$ } NMR (151 MHz,  $CDCl_3$ )**  $\delta$  171.0, 157.8, 143.9, 132.1, 129.8, 127.9, 119.2, 55.4, 52.1, 37.8, 21.6, 19.6, 15.8. **HRMS (ESI-TOF)  $m/z$ :**  $[M+H]^+$  Calcd for  $C_{15}H_{20}NO_4S$  310.1108; Found 310.1115. **TLC:**  $R_f$  = 0.15 (20:1  $CHCl_3$ :MeOH).

(*E*)-2-(4-methyl-1-tosylpyrrolidin-3-ylidene)butanoic acid (**2j**). Following General Procedure B with enyne **1j** and purification of the crude material via recrystallization from  $CH_2Cl_2$ /hexane afforded **2j** as a colorless solid in 91% yield (0.46 mmol, 147 mg). Mp 83–84 °C.  **$^1H$  NMR (600 MHz,  $CDCl_3$ )**  $\delta$  7.71 (d,  $J$  = 8.2 Hz, 2H), 7.35 (d,  $J$  = 8.2 Hz, 2H), 4.20 (d,  $J$  = 16.4 Hz, 1H), 3.64 (d,  $J$  = 16.4 Hz, 1H), 3.60 – 3.52 (m, 1H), 3.33 (d,  $J$  = 9.1 Hz, 1H), 2.98 (dd,  $J$  = 9.1, 6.1 Hz, 1H), 2.43 (s, 3H), 2.17 (dq,  $J$  = 14.7, 7.4 Hz, 1H), 2.09 (dq,  $J$  = 14.4, 7.4 Hz, 1H), 1.18 (d,  $J$  = 7.0 Hz, 3H), 0.98 (t,  $J$  = 7.4 Hz, 3H).  **$^{13}C$  { $^1H$ } NMR (151 MHz,  $CDCl_3$ )**  $\delta$  171.5, 157.2, 144.0, 132.0, 129.8, 127.9, 125.7, 55.2, 51.2, 37.7, 23.8, 21.6, 19.7, 12.8. **HRMS (ESI,  $m/z$ ):** calcd for  $C_{16}H_{21}NO_4S[M+H]^+$ : 324.1265, found 324.1264. **TLC:**  $R_f$  = 0.15 (20:1  $CHCl_3$ :MeOH).

(*Z*)-2-(4-methyl-1-tosylpyrrolidin-3-ylidene)-2-(trimethylsilyl)acetic acid (**2k**).

Following General Procedure B with enyne **1k** and purification of the crude material via column chromatography (100% CHCl<sub>3</sub> → 10:1 CHCl<sub>3</sub>:MeOH) afforded **2k** as a tan oil in 76% yield (0.38 mmol, 140 mg). **<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 7.68 (d, *J* = 8.2 Hz, 2H), 7.34 (d, *J* = 8.2 Hz, 2H), 4.08 (d, *J* = 15.4 Hz, 1H), 3.61 (d, *J* = 15.4 Hz, 1H), 3.27 – 3.19 (m, 1H), 3.19 – 3.11 (m, 1H), 2.98 (dd, *J* = 9.1, 6.1 Hz, 1H), 2.43 (s, 3H), 1.13 (d, *J* = 7.0 Hz, 3H), 0.15 (s, 9H). **<sup>13</sup>C {<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>)** δ 176.0, 160.2, 144.0, 131.9, 129.8, 128.3, 127.8, 54.3, 51.3, 39.0, 21.5, 19.9, –0.7. **HRMS (ESI-TOF) *m/z***: [M+H]<sup>+</sup> Calcd for C<sub>17</sub>H<sub>26</sub>NO<sub>4</sub>SSi 368.1347; Found 368.1325. **TLC**: R<sub>f</sub> = 0.19 (30:1 CHCl<sub>3</sub>:MeOH).

(*E*)-2-(4-methyl-5-phenyl-1-tosylpyrrolidin-3-ylidene)propanoic acid (**2l**). Following General Procedure B with enyne **1l** and purification of the crude material via column chromatography (100% CHCl<sub>3</sub> → 100:1 CHCl<sub>3</sub>:MeOH) afforded **2l** as a colorless oil in 82% yield (0.41 mmol, 158 mg, d.r. = 3:1 *anti:syn*). Separation of the diastereomers was not possible and they were characterized as a mixture. ***Anti* isomer: <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)** δ 7.54 (d, *J* = 8.2 Hz, 2H), 7.29 (m, *J* = 8.6 Hz, 2H), 7.23 – 7.16 (m, 4H), 7.06 (m, 1H), 4.77 (s, 1H), 4.31 (dt, *J* = 16.9, 1.6 Hz, 1H), 4.21 (dd, *J* = 16.9, 1.1 Hz, 1H), 3.64 (m, 1H), 2.38 (s, 3H), 1.82 (s, 3H), 1.05 (d, *J* = 7.0 Hz, 3H). **<sup>13</sup>C {<sup>1</sup>H} NMR (151 MHz, CDCl<sub>3</sub>)** δ 171.7, 157.7, 143.4, 144.7, 129.5, 128.6, 128.4, 127.6, 127.5, 127.2, 126.0, 71.1, 51.7, 47.1, 21.5, 20.4, 16.0. ***Syn* isomer: <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)** δ 7.54 (d, *J* = 8.2 Hz, 2H), 7.29 (m, 7H), 4.39 (d, *J* = 17.5 Hz, 1H), 4.25 (d, *J* = 6.3 Hz, 1H), 4.04 (d, *J* = 16.4 Hz, 1H), 3.71 – 3.57 (m, 1H), 2.43 (s, 3H), 1.79 (s, 3H), 0.81 (d, *J* = 7.1 Hz, 1H). **<sup>13</sup>C {<sup>1</sup>H} NMR (151 MHz, CDCl<sub>3</sub>)** δ 172.4, 155.9, 153.9, 144.1, 135.7, 129.6, 128.7, 128.2, 127.8, 120.0, 118.8, 69.0, 53.7, 44.3, 21.6, 20.2, 15.4. **HRMS (ESI-TOF) *m/z***: [M+H]<sup>+</sup> Calcd for C<sub>21</sub>H<sub>24</sub>NO<sub>4</sub>S 386.1421; Found 386.1417. **TLC**: R<sub>f</sub> = 0.43 (10:1 CHCl<sub>3</sub>:MeOH).

(*E*)-2-(4,5-dimethyl-1-tosylpyrrolidin-3-ylidene)propanoic acid (**2m**). Following General Procedure B with enyne **1m** and purification of the crude material via column chromatography (100% CHCl<sub>3</sub> → 100:1 CHCl<sub>3</sub>:MeOH) afforded **2m** as a colorless oil in 90% yield (0.45 mmol, 146 mg, d.r. = 1:1 *anti:syn*). Separation of the diastereomers was not possible and they were characterized as a mixture. **Anti isomer:** <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.76 (d, *J* = 8.1 Hz, 2H), 7.31 (d, *J* = 8.1 Hz, 2H), 4.26 (d, *J* = 17.2 Hz, 1H), 3.78 (q, *J* = 6.5 Hz, 1H), 3.66 (dd, *J* = 17.3, 1.4 Hz, 1H), 3.29 (q, *J* = 7.0 Hz, 1H), 2.42 (s, 3H), 1.80 (s, 3H), 1.09 (d, *J* = 7.0 Hz, 3H), 0.78 (d, *J* = 7.0 Hz, 3H). <sup>13</sup>C {<sup>1</sup>H} NMR (151 MHz, CDCl<sub>3</sub>) δ 172.1, 158.1, 143.7, 136.4, 129.9, 127.4, 120.4, 63.9, 50.4, 45.7, 21.8, 19.5, 16.0, 15.5. **Syn isomer:** <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.69 (d, *J* = 8.1 Hz, 2H), 7.34 (d, *J* = 8.1 Hz, 2H), 4.15 – 4.07 (m, 1H), 4.03 (dt, *J* = 16.9, 1.5 Hz, 1H), 3.43 (sept, *J* = 6.6 Hz, 1H), 3.06 (sept, *J* = 6.3 Hz, 1H), 2.43 (s, 3H), 1.74 (s, 3H), 1.40 (d, *J* = 6.4 Hz, 3H), 1.13 (d, *J* = 6.5 Hz, 3H). <sup>13</sup>C {<sup>1</sup>H} NMR (151 MHz, CDCl<sub>3</sub>) δ 172.1, 156.7, 144.1, 132.3, 130.0, 128.1, 118.7, 59.8, 54.4, 43.3, 21.8, 19.5, 16.2, 13.9. **HRMS (ESI-TOF)** *m/z*: [M+H]<sup>+</sup> Calcd for C<sub>16</sub>H<sub>22</sub>NO<sub>4</sub>S 324.1270; Found 324.1259. **TLC:** R<sub>f</sub> = 0.23 (30:1 CHCl<sub>3</sub>:MeOH).

Methyl (*E*)-2-(1-benzoyl-4-methylpyrrolidin-3-ylidene)propanoate (**2n**). Following General Procedure B followed by General Procedure C with enyne **1n** and purification of the crude material via column chromatography (3:1 hexane:EtOAc) afforded **2n** as a colorless oil in 74% yield (0.37 mmol, 96 mg). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.49 (m, 2H), 7.42 (m, 3H), 4.70 (d, *J* = 19.0 Hz, 1H), 4.17 (d, *J* = 19.0 Hz, 1H), 3.74 (s, 3H), 3.64 (m, 2H), 3.39 (d, *J* = 9.9 Hz, 1H), 1.89 (s, 3H), 1.11 (d, *J* = 6.7 Hz, 3H). <sup>13</sup>C {<sup>1</sup>H} NMR (151 MHz, CDCl<sub>3</sub>) δ 170.0, 167.4, 154.8, 136.1, 130.1, 128.4, 127.2, 119.8, 56.7, 51.5, 49.8, 38.0, 19.7, 15.9. **HRMS (ESI-TOF)** *m/z*:

[M+Na]<sup>+</sup> Calcd for C<sub>16</sub>H<sub>19</sub>NO<sub>3</sub>Na 296.1263; Found 296.1247. **TLC:** R<sub>f</sub> = 0.17 (3:1 hexane:EtOAc).

(*E*)-2-(1-(*tert*-butoxycarbonyl)-4-methylpyrrolidin-3-ylidene)propanoic acid (**2o**). Following General Procedure B with enyne **1o** and purification of the crude material via column chromatography (100% CHCl<sub>3</sub> → 100:1 CHCl<sub>3</sub>:MeOH) afforded **2o** as a colorless oil in 57% yield (0.29 mmol, 73 mg). Some peaks in the <sup>1</sup>H and <sup>13</sup>C NMR spectra appear as broad multiplets due to the Boc group. **<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)** δ 4.25 – 4.03 (br m, 1H), 4.03 – 3.84 (br m, 1H), 3.61 (br s, 1H), 3.35 (br m, 2H), 1.76 (br s, 2H), 1.40 (s, 9H), 1.09 (d, *J* = 7.0 Hz, 3H). **<sup>13</sup>C {<sup>1</sup>H} NMR (151 MHz, CDCl<sub>3</sub>)** δ 171.2, 155.0, 118.5, 79.8, 53.7 (br m), 50.3, 38.0 (br m), 28.5, 20.5, 15.8, 8.9. **HRMS (ESI-TOF) *m/z*:** [(M+NH<sub>4</sub>) – H<sub>2</sub>O]<sup>+</sup> Calcd for C<sub>13</sub>H<sub>23</sub>N<sub>2</sub>O<sub>3</sub> 255.1701; Found 255.1703. **TLC:** R<sub>f</sub> = 0.43 (10:1 CHCl<sub>3</sub>:MeOH).

(*E*)-2-(4-methyldihydrofuran-3(2*H*)-ylidene)propanoic acid (**2p**). Following General Procedure B with enyne **1p** and purification of the crude material via column chromatography (100% CHCl<sub>3</sub> → 100:1 CHCl<sub>3</sub>:MeOH) afforded **2p** as a colorless oil in 72% yield (0.36 mmol, 56 mg). **<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)** δ 4.58 (d, *J* = 16.0 Hz, 1H), 4.31 (d, *J* = 17.3 Hz, 1H), 3.85-3.79 (m, 2H), 3.57 (m, 1H), 1.80 (s, 3H), 1.21 (d, *J* = 7.0 Hz, 3H). **<sup>13</sup>C {<sup>1</sup>H} NMR (151 MHz, CDCl<sub>3</sub>)** δ 171.9, 162.3, 116.7, 76.2, 71.4, 38.9, 18.9, 15.5. **HRMS (ESI-TOF) *m/z*:** [(M+H) – H<sub>2</sub>O]<sup>+</sup> Calcd for C<sub>8</sub>H<sub>11</sub>O<sub>2</sub> 139.0754; Found 139.0754. **TLC:** R<sub>f</sub> = 0.44 (10:1 CHCl<sub>3</sub>:MeOH).

Methyl (*E*)-2-(4-methyldihydrofuran-3(2*H*)-ylidene)-2-phenylacetate (**2q**). Following General Procedure B followed by General Procedure C with enyne **1q** and purification of the crude material via column chromatography (10:1 hexane:EtOAc) afforded **2q** as a colorless oil in 60% yield (0.3 mmol, 70 mg). **<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)** δ 7.36 (t, *J* = 7.3 Hz, 2H), 7.30 (t, *J*



= 7.2 Hz, 1H), 7.14 (d,  $J$  = 7.3 Hz, 2H), 4.31 (d,  $J$  = 16.1 Hz, 1H), 4.00 (d,  $J$  = 16.1 Hz, 1H), 3.92 (dd,  $J$  = 8.5, 5.6 Hz, 1H), 3.78 (d,  $J$  = 8.5 Hz, 1H), 3.71 (s, 3H), 3.68 (m, 1H), 1.30 (d,  $J$  = 7.0 Hz, 3H).  $^{13}\text{C}$  { $^1\text{H}$ } NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  166.8, 162.1, 137.4, 128.8, 128.6, 127.7, 124.6, 76.1, 71.5, 51.9, 38.7, 18.9. HRMS (ESI-TOF)  $m/z$ :  $[\text{M}+\text{H}]^+$  Calcd for  $\text{C}_{14}\text{H}_{17}\text{O}_3$  233.2824; Found 233.2831. TLC:  $R_f$  = 0.23 (10:1 hexane:EtOAc).

*2-(4-Methylenetetrahydro-2H-pyran-3-yl)acetic acid (4a)*. Following General Procedure B with enyne **3a** and purification of the crude material via column chromatography (100%  $\text{CHCl}_3 \rightarrow$  10:1  $\text{CHCl}_3$ :MeOH) afforded **4a** as a colorless oil in 25% yield (0.13 mmol, 20 mg).  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  4.81 (s, 1H), 4.76 (s, 1H), 3.78 (dd,  $J$  = 11.0, 3.8 Hz, 1H), 3.70 (dq,  $J$  = 15.1, 6.7, 3.0 Hz, 2H), 3.49 (dd,  $J$  = 10.9, 5.3 Hz, 1H), 2.76 (dt,  $J$  = 11.0, 6.7 Hz, 1H), 2.62 (dd,  $J$  = 15.9, 6.7 Hz, 1H), 2.52 (dd,  $J$  = 15.9, 7.7 Hz, 1H), 2.38 (dt,  $J$  = 12.0, 5.3 Hz, 1H), 2.24 (dt,  $J$  = 13.8, 5.3 Hz, 1H).  $^{13}\text{C}$  { $^1\text{H}$ } NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  174.7, 146.0, 108.6, 72.8, 69.8, 40.2, 34.2, 34.2. HRMS (ESI-TOF)  $m/z$ :  $[\text{M}+\text{H}]^+$  Calcd for  $\text{C}_8\text{H}_{13}\text{O}_3$  157.0859; Found 157.0847. TLC:  $R_f$  = 0.43 (10:1  $\text{CHCl}_3$ :MeOH).

*2-(4-Methylene-1-tosylpiperidin-3-yl)acetic acid (4b)*. Following General Procedure B with enyne **3b** at 60 °C and purification of the crude material via column chromatography (100%  $\text{CHCl}_3 \rightarrow$  10:1  $\text{CHCl}_3$ :MeOH) afforded **4b** as a colorless solid in 81% yield (0.41 mmol, 125 mg). Mp 160–161 °C.  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  7.63 (d,  $J$  = 8.3 Hz, 2H), 7.31 (d,  $J$  = 8.3 Hz, 2H), 4.76 (d,  $J$  = 13.5 Hz, 2H), 3.25 – 3.19 (m, 1H), 3.04 (d,  $J$  = 4.8 Hz, 2H), 2.91 (ddd,  $J$  = 11.4, 8.5, 4.0 Hz, 1H), 2.84 (m, 1H), 2.61 (d,  $J$  = 1.4 Hz, 2H), 2.42 (m, 4H), 2.26 (ddd,  $J$  = 13.5, 6.2, 4.0 Hz, 1H).  $^{13}\text{C}$  { $^1\text{H}$ } NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  176.5, 145.0, 143.8, 133.5, 129.8, 127.7, 110.4, 51.6, 47.9, 38.8, 35.3, 32.5, 21.7. HRMS (ESI-TOF)  $m/z$ :  $[\text{M}+\text{H}]^+$  Calcd for  $\text{C}_{15}\text{H}_{20}\text{NO}_4\text{S}$  310.1113; Found 310.1104. TLC:  $R_f$  = 0.33 (10:1  $\text{CHCl}_3$ :MeOH).

2-(5,5-bis(methoxycarbonyl)-2-methylenecyclohexyl)acetic acid (**4c**). Following General Procedure B with enyne **3c** and purification of the crude material via column chromatography (100% CHCl<sub>3</sub> → 10:1 CHCl<sub>3</sub>:MeOH) afforded **4c** as a colorless solid in 44% yield (0.22 mmol, 59 mg). Mp 102–104 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 4.78 (s, 1H), 4.60 (s, 1H), 3.79 (s, 3H), 3.70 (s, 3H), 2.66 (m, 2H), 2.51 (dt, *J* = 13.0, 2.8 Hz, 1H), 2.45 (dq, *J* = 13.0, 3.1, 2.8 Hz, 1H), 2.39 – 2.30 (m, 2H), 2.22 (td, *J* = 13.6, 4.3 Hz, 1H), 1.76 (td, *J* = 13.2, 4.5 Hz, 1H), 1.58 (t, *J* = 12.5 Hz, 1H). <sup>13</sup>C {<sup>1</sup>H} NMR (151 MHz, CDCl<sub>3</sub>) δ 176.4, 172.4, 171.3, 148.6, 106.5, 55.3, 53.0, 52.9, 38.5, 37.2, 35.7, 33.0, 32.8. HRMS (ESI-TOF) *m/z*: [(M+H) – H<sub>2</sub>O]<sup>+</sup> Calcd for C<sub>13</sub>H<sub>17</sub>O<sub>5</sub> 253.1071; Found 253.1073. TLC: R<sub>f</sub> = 0.31 (10:1 CHCl<sub>3</sub>:MeOH).

2-(3-methylenetetrahydro-2H-pyran-4-yl)acetic acid (**4d**). Following General Procedure B with enyne **3d** and purification of the crude material via column chromatography (100% CHCl<sub>3</sub> → 10:1 CHCl<sub>3</sub>:MeOH) afforded **4d** as a colorless oil in 15% yield (0.08 mmol, 12 mg). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 4.92 (s, 1H), 4.77 (s, 1H), 4.17 (d, *J* = 12.2 Hz, 1H), 4.00 – 3.91 (m, 2H), 3.63 (td, *J* = 11.3, 2.6 Hz, 1H), 2.82 – 2.69 (m, 2H), 2.40 (dd, *J* = 15.3, 7.2 Hz, 1H), 1.92 – 1.85 (m, 1H), 1.51 (dtd, *J* = 13.1, 10.7, 4.2 Hz, 1H). <sup>13</sup>C {<sup>1</sup>H} NMR (151 MHz, CDCl<sub>3</sub>) δ 175.9, 145.9, 108.4, 72.9, 67.2, 36.7, 36.6, 34.0. HRMS (ESI-TOF) *m/z*: [M+H]<sup>+</sup> Calcd for C<sub>8</sub>H<sub>13</sub>O<sub>3</sub> 157.0859; Found 157.0866. TLC: R<sub>f</sub> = 0.33 (10:1 CHCl<sub>3</sub>:MeOH).

2-(3-methylene-1-tosylpiperidin-4-yl)acetic acid (**4e**). Following General Procedure B with enyne **3e** and purification of the crude material via column chromatography (100% CHCl<sub>3</sub> → 10:1 CHCl<sub>3</sub>:MeOH) afforded **4e** as a tan oil in 52% yield (0.26 mmol, 80 mg). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.65 (d, *J* = 8.3 Hz, 2H), 7.33 (d, *J* = 8.3 Hz, 2H), 5.02 (s, 1H), 4.79 (s, 1H), 4.01 (d, *J* = 12 Hz, 1H), 3.66 – 3.59 (m, 1H), 3.06 (d, *J* = 12 Hz, 1H), 2.71 – 2.58 (m, 2H), 2.44 (m, 4H), 2.31 (dd, *J* = 15.9, 7.7 Hz, 1H), 1.89 (dq, *J* = 12.6, 4.2 Hz, 1H), 1.43 (dtd, *J* = 13.1,

10.9, 4.2 Hz, 1H).  $^{13}\text{C}$  { $^1\text{H}$ } NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  176.5, 143.7, 142.4, 132.9, 129.7, 127.8, 110.7, 52.7, 45.6, 36.9, 36.3, 31.4, 21.6. HRMS (ESI-TOF)  $m/z$ : [M+H] $^+$  Calcd for  $\text{C}_{15}\text{H}_{20}\text{NO}_4\text{S}$  310.1113; Found 310.1108. TLC:  $R_f$  = 0.42 (10:1  $\text{CHCl}_3$ :MeOH).

2-(4,4-bis(methoxycarbonyl)-2-methylenecyclohexyl)acetic acid (**4f**). Following General Procedure B with enyne **3f** and purification of the crude material via column chromatography (100%  $\text{CHCl}_3 \rightarrow$  10:1  $\text{CHCl}_3$ :MeOH) afforded **4f** as a colorless oil in 57% yield (0.29 mmol, 77 mg).  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  4.84 (s, 1H), 4.70 (s, 1H), 3.72 (s, 3H), 3.71 (s, 3H), 2.91 (dd,  $J$  = 13.5, 1.6 Hz, 1H), 2.68 – 2.53 (m, 3H), 2.35 (dd,  $J$  = 15.1, 7.3 Hz, 2H), 1.95–1.86 (m, 2H), 1.48 – 1.37 (m, 1H).  $^{13}\text{C}$  { $^1\text{H}$ } NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  176.6, 171.9, 171.0, 145.5, 109.8, 57.0, 52.9, 52.7, 40.0, 38.5, 37.0, 30.4, 30.3. HRMS (ESI-TOF)  $m/z$ : [M+H] $^+$  Calcd for  $\text{C}_{13}\text{H}_{19}\text{O}_6$  271.1176; Found 271.1173. TLC:  $R_f$  = 0.36 (10:1  $\text{CHCl}_3$ :MeOH).

Dimethyl(*E*)-3-ethylidene-4-(2-methoxy-2-oxo-1-phenylethyl)cyclopentane-1,1-dicarboxylate (**4g**). Following General Procedure B with enyne **3g** at 60 °C followed by General Procedure C and purification of the crude material via column chromatography (4:1 hexane:EtOAc) afforded **4g** as a colorless oil in 60% yield (0.30 mmol, 108 mg).  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  7.34–7.24 (m, 5H), 5.30 (m, 1H), 3.70 (s, 3H), 3.67 (s, 3H), 3.64 (s, 3H), 3.49 (d,  $J$  = 10.7 Hz, 1H), 3.01 (d,  $J$  = 16.6 Hz, 1H), 2.90 (d,  $J$  = 19.9 Hz, 1H), 2.24 – 2.15 (m, 1H), 1.64 – 1.59 (m, 3H), 1.58 (s, 2H).  $^{13}\text{C}$  { $^1\text{H}$ } NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  173.9, 172.4, 172.1, 140.7, 137.5, 128.7, 128.6, 127.5, 117.9, 57.9, 56.2, 52.83, 52.77, 52.0, 45.3, 37.8, 36.9, 14.8. HRMS (ESI-TOF)  $m/z$ : [M+H] $^+$  Calcd for  $\text{C}_{20}\text{H}_{25}\text{O}_6$  361.1651; Found 361.1651. TLC:  $R_f$  = 0.43 (3:1 hexane:EtOAc).

*EtLi-d<sub>5</sub>*.<sup>20</sup> An oven-dried 25 mL bomb flask was evacuated and refilled with Ar. Pentane (15 mL) was added to the flask, followed by  $\text{Li}^0$  (~400 mg, 57 mmol, 10 equiv) in small chunks.

EtBr- $d_5$  was added (0.43 mL, 5.7 mmol, 1 equiv) and the flask was sealed. The mixture was stirred vigorously at 40 °C for 16 hours. In a N<sub>2</sub>-filled glovebox, the mixture was filtered through Celite. The filtrate was concentrated under vacuum to give EtLi- $d_5$  as a colorless, crystalline solid (202 mg, 4.9 mmol, 85%). <sup>13</sup>C {<sup>1</sup>H} NMR (151 MHz, C<sub>6</sub>D<sub>6</sub>) δ 10.1 (sept), -1.3 (m).

ZnEt<sub>2</sub>- $d_{10}$ . The deuterated zinc reagent was generated in situ by a modified literature procedure<sup>21</sup> and used without isolation. ZnCl<sub>2</sub> (16 mg, 0.12 mmol, 1 equiv) was dissolved in 1 mL Et<sub>2</sub>O in a 4 mL vial. EtLi- $d_5$  (10 mg, 0.24 mmol, 2 equiv) was added in 0.5 mL Et<sub>2</sub>O and the solution became turbid. After stirring for 1 hour at 23 °C, 0.5 mL pentane was added to precipitate LiCl and the mixture was filtered. The filtrate was concentrated under vacuum and titrated with I<sub>2</sub> before use.<sup>22</sup>

(Z)-2-(4,4-bis(methoxycarbonyl)-2-(methyl- $d$ )cyclopentylidene)propanoic acid (**2a-D**). Following General Procedure A with enyne **1a** and ZnEt<sub>2</sub>- $d_{10}$  (2.5 equiv) followed by purification of the crude material via column chromatography (100% CHCl<sub>3</sub> → 10:1 CHCl<sub>3</sub>:MeOH) afforded **2a-D** as a colorless solid in 85% yield (0.043 mmol, 12 mg) with 97% deuterium incorporation. Mp 65–68 °C. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 3.77 (s, 3H), 3.73 (s, 3H), 3.60 (m, 1H), 3.30 (d, *J* = 18.3 Hz, 1H), 2.98 (d, *J* = 18.3 Hz, 1H), 2.61 (dd, *J* = 13.5, 8.2 Hz, 1H), 2.19 (dd, *J* = 13.5, 3.5 Hz, 1H), 1.88 (s, 3H), 1.04 (d, *J* = 7.1 Hz, 2H). <sup>13</sup>C {<sup>1</sup>H} NMR (151 MHz, CDCl<sub>3</sub>) δ 172.5, 172.3, 172.2, 162.7, 119.2, 58.1, 53.0, 52.9, 41.8, 40.8, 37.7, 20.2 (t), 16.4. HRMS (ESI-TOF) *m/z*: [M+H]<sup>+</sup> Calcd for C<sub>13</sub>H<sub>18</sub>DO<sub>6</sub> 272.1244; Found 272.1238. TLC: R<sub>f</sub> = 0.20 (40:1 CHCl<sub>3</sub>:MeOH).

(Z)-2-(4-(methylene- $d$ )-1-tosylpiperidin-3-yl)acetic acid (**4b-D**). Following General Procedure A with enyne **3b** and ZnEt<sub>2</sub>- $d_{10}$  (2.5 equiv) at 60 °C and purification of the crude

material via column chromatography (100% CHCl<sub>3</sub> → 100:1 CHCl<sub>3</sub>:MeOH) afforded **4b-D** as a colorless solid in 61% yield (0.031 mmol, 10 mg) with >99% deuterium incorporation. Mp 158–160 °C. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.63 (d, *J* = 8.1 Hz, 2H), 7.31 (d, *J* = 8.1 Hz, 2H), 4.75 (s, 1H), 3.28 – 3.17 (m, 1H), 3.04 (d, *J* = 4.5 Hz, 2H), 2.91 (ddd, *J* = 11.4, 8.4, 4.0 Hz, 1H), 2.88 – 2.80 (m, 1H), 2.61 (d, *J* = 7.2 Hz, 2H), 2.45 (m, 1H), 2.42 (s, 3H), 2.30 – 2.22 (m, 1H). <sup>13</sup>C {<sup>1</sup>H} NMR (151 MHz, CDCl<sub>3</sub>) δ 175.2, 144.8, 143.6, 133.4, 129.7, 127.6, 110.0 (t), 51.4, 47.8, 38.7, 36.0, 32.3, 21.5. HRMS (ESI-TOF) *m/z*: [M+H]<sup>+</sup> Calcd for C<sub>15</sub>H<sub>19</sub>DNO<sub>4</sub>S 311.1170; Found 311.1167. TLC: R<sub>f</sub> = 0.33 (10:1 CHCl<sub>3</sub>:MeOH).

*N*-(but-2-yn-1-yl)-4-methyl-*N*-(1-phenylallyl)benzenesulfonamide (**11**). 1-Phenylprop-2-en-1-ol (154 mg, 1.15 mmol, 1 equiv) was dissolved in 10 mL dry THF under N<sub>2</sub>. PPh<sub>3</sub> (477 mg, 1.81 mmol, 1.6 equiv) and TsNHBoc (325 mg, 1.2 mmol, 1.05 equiv) were added and the solution was cooled to 0 °C. DEAD (0.8 mL of 40% solution in toluene, 1.9 mmol, 1.7 equiv) was added dropwise and the reaction was stirred for 1 hour at 0 °C then 8 hours at room temperature. The solution was diluted with EtOAc and quenched with sat. NH<sub>4</sub>Cl<sub>(aq)</sub>. The aqueous phase was extracted 2 x 5 mL EtOAc. The combined organic phase was washed with 2 x 10 mL brine and dried over Na<sub>2</sub>SO<sub>4</sub>. Solvent was removed and the yellow residue was dissolved in 5 mL DCM and treated with 3 mL TFA. The solution was stirred for 2 hours and solvent was removed to give a yellow oil. Purification was accomplished via column chromatography on silica using 4:1 hexane:EtOAc to give 4-methyl-*N*-(1-phenylallyl)-*p*-toluenesulfonamide as a slightly yellow oil (233 mg, 0.81 mmol, 70%). The spectroscopic data for this compound are in agreement with the published spectra.<sup>23</sup> 4-Methyl-*N*-(1-phenylallyl)-*p*-toluenesulfonamide (66 mg, 0.23 mmol, 1 equiv) was dissolved in 6 mL dry THF and treated with NaH (60% in mineral oil, 12 mg, 0.28 mmol, 1.2 equiv). The mixture was stirred until the evolution of H<sub>2</sub> ceased (30 minutes). 1-

bromobut-2-yne (0.03 mL, 0.3 mmol, 1.3 equiv) was added and the mixture was stirred for 12 hours. The reaction was diluted with EtOAc and quenched with sat.  $\text{NH}_4\text{Cl}_{(\text{aq})}$ . The aqueous phase was extracted 2 x 5 mL EtOAc and the combined organic phase was washed with brine and dried over  $\text{MgSO}_4$ . The product was purified via column chromatography on silica using 10:1 hexane:EtOAc giving a colorless oil (41 mg, 0.12 mmol, 65%). The spectroscopic data for this compound are in agreement with the published spectra.<sup>24</sup>  **$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )**  $\delta$  7.74 (d,  $J$  = 8.3 Hz, 2H), 7.25 (d,  $J$  = 3.3 Hz, 2H), 7.23 – 7.16 (m, 5H), 6.14 (ddd,  $J$  = 17.1, 10.3, 7.6 Hz, 1H), 5.56 (d,  $J$  = 7.6 Hz, 1H), 5.19 (dt,  $J$  = 10.3, 1.2 Hz, 1H), 5.10 (dt,  $J$  = 17.1, 1.3 Hz, 1H), 4.01 (dq,  $J$  = 18.2, 2.4 Hz, 1H), 3.70 (dq,  $J$  = 18.2, 2.4 Hz, 1H), 2.37 (s, 3H), 1.51 (t,  $J$  = 2.4 Hz, 3H).  **$^{13}\text{C}$  { $^1\text{H}$ } NMR (151 MHz,  $\text{CDCl}_3$ )**  $\delta$  143.0, 138.2, 137.9, 134.2, 129.0, 128.4, 128.1, 127.9, 127.8, 119.0, 80.7, 74.5, 63.7, 34.5, 21.6, 3.4.

*N*-allyl-*N*-(but-2-yn-1-yl)benzamide (**1n**). A 50 mL RBF was charged with 15 mL DMF and 60 mg of a 60% dispersion of NaH in mineral oil (1.3 mmol, 1.3 equiv) under  $\text{N}_2$ . The mixture was cooled in an ice bath and *N*-allylbenzamide (162 mg, 1 mmol, 1 equiv) was added as a solution in 5 mL DMF. The mixture was stirred at 0 °C for 20 minutes, then 1-bromobut-2-yne (0.11 mL, 1.26 mmol, 1.26 equiv) was added dropwise. The mixture was stirred at room temperature for 12 hours, then the reaction mixture was diluted with EtOAc and quenched with sat.  $\text{NH}_4\text{Cl}_{(\text{aq})}$ . The aqueous phase was extracted 4 x 5 mL EtOAc and the combined organic phase was washed with 2 x 10 mL  $\text{H}_2\text{O}$ , 2 x 10 mL brine, and dried over  $\text{MgSO}_4$ . Column chromatography on silica with 10:1 hexane:EtOAc gave the product as a slightly yellow oil (203 mg, 0.95 mmol, 95%). The  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra are broad due to restricted rotation around the benzamide.  **$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )**  $\delta$  7.60-7.38 (br m, 5H), 5.95-5.69 (br m, 1H), 5.26 (dq,  $J$  = 10.2, 1.4 Hz, 2H), 4.38-4.19 (br m, 2H), 4.06-3.83 (br m, 2H), 1.86 (s, 3H)  **$^{13}\text{C}$  { $^1\text{H}$ }**

**NMR (151 MHz, CDCl<sub>3</sub>)**  $\delta$  171.4 (br), 135.9, 132.8 (br), 130.0, 128.5, 127.1 (br), 118.1 (br), 80.3 (br) 74.1, 49.0 (br), 36.4 (br), 3.7. **HRMS (ESI-TOF)  $m/z$ :** [M+H]<sup>+</sup> Calcd for C<sub>14</sub>H<sub>16</sub>NO 214.1226; Found 214.1230. **TLC:** R<sub>f</sub> = 0.15 (10:1 hexane:EtOAc).

*N*-allyl-*N*-(but-3-yn-1-yl)-*p*-toluenesulfonamide (**3b**). *N*-(but-3-yn-1-yl)-*p*-toluenesulfonamide<sup>25</sup> (850 mg, 3.8 mmol, 1 equiv) was dissolved in 10 mL of acetone. K<sub>2</sub>CO<sub>3</sub> (630 mg, 4.56 mmol, 1.2 equiv) was added, followed by allyl bromide (0.4 mL, 4.56 mmol, 1.2 equiv). The mixture was heated to reflux for 12 hours then filtered and solvent was removed. Column chromatography on silica with 10:1 hexane:EtOAc gave the product as a colorless oil (590 mg, 2.24 mmol, 59%, 83% b.r.s.m.) as well as 250 mg (1.12 mmol, 29%) of the alkyne starting material. **<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)**  $\delta$  7.74-7.66 (m, 2H), 7.35-7.26 (m, 2H), 5.66 (ddt, *J* = 16.7, 10.1, 6.4 Hz, 1H), 5.23-5.12 (m, 2H), 3.84 (dt, *J* = 6.5, 1.4 Hz, 2H), 3.32-3.23 (m, 2H), 2.49-2.46 (m, 2H), 2.42 (s, 3H), 1.96 (t, *J* = 2.7 Hz, 1H). **<sup>13</sup>C {<sup>1</sup>H} NMR (151 MHz, CDCl<sub>3</sub>)**  $\delta$  143.6, 137.0, 133.2, 130.0, 127.4, 119.5, 81.2, 70.3, 51.5, 46.2, 21.7, 19.5. **HRMS (ESI-TOF)  $m/z$ :** [M+H]<sup>+</sup> Calcd for C<sub>14</sub>H<sub>18</sub>NO<sub>2</sub>S 264.1053; Found 264.1055. **TLC:** R<sub>f</sub> = 0.30 (10:1 hexane:EtOAc).

*N*-allyl-4-methyl-*N*-(4-(trimethylsilyl)but-3-yn-1-yl)benzenesulfonamide (**1h**). A RBF was charged with *N*-allyl-*N*-(but-3-yn-1-yl)-*p*-toluenesulfonamide (**3b**) (160 mg, 0.61 mmol, 1 equiv) and 3 mL dry THF, then cooled to -78 °C under N<sub>2</sub>. 1.6 M *n*-BuLi in hexane (0.46 mL, 0.73 mmol, 1.2 equiv) was added dropwise and the solution was stirred for 10 minutes. TMSCl (0.10 mL, 0.67 mmol, 1.1 equiv) was added dropwise. The solution was stirred for 1.5 hours at -78 °C, then at room temperature overnight. The reaction was quenched with sat. NH<sub>4</sub>Cl<sub>(aq)</sub> and the aqueous layer was extracted 2 x 5 mL EtOAc. The combined organic phase was washed with 2 x 10 mL brine and dried over MgSO<sub>4</sub>. Purification via column chromatography on silica with

10:1 hexane:EtOAc gave the product as a colorless oil (185 mg, 0.55 mmol, 90%). **<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)** δ 7.75-7.69 (m, 2H), 7.34-7.28 (m, 2H), 5.73-5.61 (m, 1H), 5.24-5.14 (m, 2H), 3.86 (d, *J* = 6.4 Hz, 2H), 3.29 (t, *J* = 7.5 Hz, 2H), 2.50 (t, *J* = 5.0 Hz, 2H), 2.43 (s, 3H), 0.14 (s, 9H). **<sup>13</sup>C {<sup>1</sup>H} NMR (151 MHz, CDCl<sub>3</sub>)** δ 143.5, 137.2, 133.2, 129.9, 127.4, 119.4, 103.8, 86.8, 51.6, 46.3, 21.7, 21.0. **HRMS (ESI-TOF) *m/z*:** [M+H]<sup>+</sup> Calcd for C<sub>17</sub>H<sub>26</sub>NO<sub>2</sub>SSi 336.1448; Found 336.1448. **TLC:** R<sub>f</sub> = 0.33 (10:1 hexane:EtOAc).

*Dimethyl 2-(but-2-yn-1-yl)-2-cinnamylmalonate (3g)*. A RBF was charged with NaH (54 mg, 2.2 mmol, 1.2 equiv.) and cooled to 0 °C under N<sub>2</sub>. 10 mL of dry DMF was then added to the RBF via syringe. Dimethyl 2-(but-2-yn-1-yl)malonate<sup>26</sup> (345 mg, 1.873 mmol, 1 equiv.) was added to the RBF in 1 mL DMF and stirred for five minutes. Cinnamyl bromide (443 mg, 2.25 mmol, 1.2 equiv.) was added to the RBF dropwise. The flask was warmed to room temperature and stirred overnight. The reaction was quenched with sat. NH<sub>4</sub>Cl<sub>(aq)</sub> and water. The aqueous layer was extracted 3 x 10 mL diethyl ether. The combined organic layer was washed with 10 mL brine, then 10 mL water, and dried over MgSO<sub>4</sub>. Purification via column chromatography on silica with 20:1 hexane:EtOAc gave enyne **3g** as a colorless oil (491 mg, 1.63 mmol, 87%). **<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)** δ 7.34 – 7.27 (m, 4H), 7.23 – 7.19 (m, 1H), 6.49 (d, *J* = 15.7 Hz, 1H), 6.02 (dt, *J* = 15.7, 7.6 Hz, 1H), 3.74 (s, 6H), 2.94 (dd, *J* = 7.6, 1.2 Hz, 2H), 2.79 (q, *J* = 2.5 Hz, 2H), 1.79 (t, *J* = 2.5 Hz, 3H). **<sup>13</sup>C {<sup>1</sup>H} NMR (151 MHz, CDCl<sub>3</sub>)** δ 170.7, 137.2, 134.5, 128.6, 127.6, 126.4, 123.7, 79.2, 73.4, 57.8, 52.9, 36.1, 23.5, 3.7. **HRMS (ESI-TOF) *m/z*:** [M+H]<sup>+</sup> Calcd for C<sub>18</sub>H<sub>21</sub>O<sub>4</sub> 301.1434; Found 301.1438. **TLC:** R<sub>f</sub> = 0.40 (4:1 hexane:EtOAc).

## ASSOCIATED CONTENT

### Supporting Information



The Supporting Information is available free of charge via the Internet at <http://pubs.acs.org>. Copies of  $^1\text{H}$  NMR spectra,  $^{13}\text{C}$  NMR spectra, IR spectra, reaction optimization table, and crystallographic data for **2j**.

## AUTHOR INFORMATION

### Corresponding Author

diao@nyu.edu

### Notes

The authors declare no competing financial interest.

## ACKNOWLEDGMENTS

We thank Nadia Leonard (Chirik lab, Princeton University) for assistance in testing the EPR signal of the reaction mixture and Dr. Chunhua Hu for solving the crystal structure of **2j**. This work was supported by the National Science Foundation under award number CHE-1654483 and New York University. The cryoprobe is supported by NIH under grant number S10 OD016343.

## REFERENCES

1. (a) Behr, A. *Angew. Chem. Int. Ed.* **1988**, 27, 661. (b) Sakakura, T.; Choi, J.-C.; Yasuda, H. *Chem. Rev.* **2007**, 107, 2365. (c) Aresta, M. *Carbon Dioxide as Chemical Feedstock*; Wiley-VCH Verlag GmbH & Co. KGaA, 2010. (d) Aresta, M.; Dibenedetto, A.; Quaranta, E. *J. Catal.* **2016**, 343, 2.
2. For selected reviews, see: (a) Sakakura, T.; Choi, J.-C.; Yasuda, H. *Chem. Rev.* **2007**, 107, 2365. (b) Correa, A.; Martín, R. *Angew. Chem. Int. Ed.* **2009**, 48, 6201 (c) Cokoja, M.; Bruckmeier, C.; Rieger, B.; Herrmann, W. A.; Kühn, F. E. *Angew. Chem. Int. Ed.* **2011**, 50, 8510. (d) Tsuji, Y.; Fujihara, T. *Chem. Commun.* **2012**, 48, 9956. (e) Zhang, L.; Hou, Z.

- Chem. Sci.* **2013**, *4*, 3395. (f) Yeung, C. S.; Dong, V. M. *Top. Catal.* **2014**, *57*, 1342. (g) Liu, Q.; Wu, L.; Jackstell, R.; Beller, M. *Nat. Commun.* **2015**, *6*. (h) Yu, B.; He, L.-N. *ChemSusChem* **2015**, *8*, 52. (i) Börjesson, M.; Moragas, T.; Gallego, D.; Martin, R. *ACS Catalysis* **2016**, 6739. (j) Li, Y.; Cui, X.; Dong, K.; Junge, K.; Beller, M. *ACS Catalysis* **2016**, 1077.
3. For representative examples, see: (a) Louie, J.; Gibby, J. E.; Farnworth, M. V.; Tekavec, T. N. *J. Am. Chem. Soc.* **2002**, *124*, 15188. (b) Takimoto, M.; Nakamura, Y.; Kimura, K.; Mori, M. *J. Am. Chem. Soc.* **2004**, *126*, 5956. (c) Williams, C. M.; Johnson, J. B.; Rovis, T. *J. Am. Chem. Soc.* **2008**, *130*, 14936. (d) Zhang, L.; Cheng, J.; Carry, B.; Hou, Z. *J. Am. Chem. Soc.* **2012**, *134*, 14314. (e) Moragas, T.; Cornella, J.; Martin, R. *J. Am. Chem. Soc.* **2014**, *136*, 17702. (f) Nogi, K.; Fujihara, T.; Terao, J.; Tsuji, Y. *J. Am. Chem. Soc.* **2016**, *138*, 5547. (g) Cao, T.; Ma, S. *Org. Lett.* **2016**, *18*, 1510. (h) Zhang, Z.; Liao, L.-L.; Yan, S.-S.; Wang, L.; He, Y.-Q.; Ye, J.-H.; Li, J.; Zhi, Y.-G.; Yu, D.-G. *Angew. Chem. Int. Ed.* **2016**, *55*, 7068. (i) Butcher, T. W.; McClain, E. J.; Hamilton, T. G.; Perrone, T. M.; Kroner, K. M.; Donohoe, G. C.; Akhmedov, N. G.; Petersen, J. L.; Popp, B. V. *Org. Lett.* **2016**, *18*, 6428.
4. For examples: (a) Lomenzo, S. A.; Izenwasser, S.; Katz, J. L.; Terry, P. D.; Zhu, N.; Klein, C. L.; Trudell, M. L. *J. Med. Chem.* **1997**, *40*, 4406. (b) Signe, H.; Jeremy, R. G.; Karsten, B. M.; Orla, M. L.; Bente, F.; Arne, S.; Povl, K.-L.; Rasmus, P. C. *Curr. Top. Med. Chem.* **2006**, *6*, 1861.
5. For reviews of Ni-catalyzed reductive coupling reactions, see: (a) Montgomery, J. *Angew. Chem. Int. Ed.* **2004**, *43*, 3890. (b) Ng, S.-S.; Jamison, T. F. *Tetrahedron* **2006**, *62*, 11350. (c) Tasker, S. Z.; Standley, E. A.; Jamison, T. F. *Nature* **2014**, *509*, 299. (d) Standley, E. A.;

- Tasker, S. Z.; Jensen, K. L.; Jamison, T. F. *Acc. Chem. Res.* **2015**, *48*, 1503. (e) Weix, D. J. *Acc. Chem. Res.* **2015**, *48*, 1767. (f) Jackson, E. P.; Malik, H. A.; Sormunen, G. J.; Baxter, R. D.; Liu, P.; Wang, H.; Shareef, A.-R.; Montgomery, J. *Acc. Chem. Res.* **2015**, *48*, 1736. (g) Yan, M.; Lo, J. C.; Edwards, J. T.; Baran, P. S. *J. Am. Chem. Soc.* **2016**, *138*, 12692.
6. For a review of cycloisomerization reactions, see: Yamamoto, Y. *Chem. Rev.* **2012**, *112*, 4736.
7. Iglesias, M. J.; Blandez, J. F.; Fructos, M. R.; Prieto, A.; Álvarez, E.; Belderrain, T. R.; Nicasio, M. C. *Organometallics* **2012**, *31*, 6312.
8. Chen, M.; Weng, Y.; Guo, M.; Zhang, H.; Lei, A. *Angew. Chem. Int. Ed.* **2008**, *47*, 2279.
9. Kinetic fitting was carried out with COPASI software: Hoops, S.; Sahle, S.; Gauges, R.; Lee, C.; Pahle, J.; Simus, N.; Singhal, M.; Xu, L.; Mendes, P.; Kummer, U. *Bioinformatics* **2006**, *22*, 3067.
10. (a) Aresta, M.; Nobile, C. F. *J. Chem. Soc., Chem. Commun.* **1975**, 636. (b) Aresta, M.; Nobile, C. F. *J. Chem. Soc., Dalton Trans.* **1977**, 708.
11. Yeung, C. S.; Dong, V. M. *J. Am. Chem. Soc.* **2008**, *130*, 7826.
12. (a) Schaefer, D.; Hoberg, H. *J. Organomet. Chem.*, **1983**, *251*, C51 b) Hoberg, H.; Peres, Y.; Kruger, C.; Tsay, Y.-H. *Angew. Chem., Int. Ed. Engl.* 1987, **26**, 771 c) Saito, S.; Nakagawa, S.; Koizumi, T.; Hirayama, K.; Yamamoto, Y. *J. Org. Chem.*, **1999**, *64*, 3975.
13. Ogoshi, S.; Arai, T.; Ohashi, M.; Kurosawa, H. *Chem. Commun.* **2008**, 1347.
14. Wilson, G. L. O.; Abraha, M.; Krause, J. A.; Guan, H. R. *Dalton T* **2015**, *44*, 12128.
15. Wu, J.; Hazari, N.; Incarvito, C. D. *Organometallics* **2011**, *30*, 3142.
16. (a) Kossler, D.; Cramer, N. *J. Am. Chem. Soc.* **2015**, *137*, 12478. (b) Ishida, M.; Tanaka, K. *Org. Lett.*, **2013**, *15*, 2120. (c) Trost, B. M.; Shi, Y. *J. Am. Chem. Soc.*, **1993**, *115*, 12491.

- 
- (d) Pardo-Rodríguez, V.; Buñuel, E.; Collado-Sanza, D.; Cárdenas, D. *J. Chem. Commun.*, **2012**, 48, 10517. (e) Zachary, D.-G. W.; Letitia, Y. J.; Ian, T. A. *J. Am. Chem. Soc.*, **2016**, 138, 14570. (f) Miura, T.; Sasaki, T.; Nakazawa, H.; Murakami, M. *J. Am. Chem. Soc.*, **2005**, 127, 1390. (g) Gibson, S. E.; Hardick, D. J.; Haycock, P. R.; Kaufmann, K. A. C.; Miyazaki, A.; Tozer, M. J.; White, A. J. P. *Chem. Eur. J.*, **2007**, 13, 7099. (h) Candito, D. A.; Lautens, M. *Synlett*, 2011, 14, 1987. (i) Sylvester, K. T.; Chirik, P. J. *J. Am. Chem. Soc.*, **2009**, 131, 8772. (j) Berk, S. C.; Grossman, R. B.; Buchwald, S. L. *J. Am. Chem. Soc.*, **1994**, 116, 8593. (k) Morimoto, T.; Fuji, K.; Tsutsumi, K.; Kakiuchi, K. *J. Am. Chem. Soc.*, **2002**, 124, 3806. (l) Daniel, D.; Middleton, R.; Henry, H. L.; Okamura, W. H. *J. Org. Chem.*, **1996**, 61, 5617. (m) Kavanagh, Y.; Chaney, C. M.; Muldoon, J.; Evans, P. *J. Org. Chem.*, **2008**, 73, 8601. (n) Trost, B. M.; Ball, Z. T. *J. Am. Chem. Soc.*, **2005**, 127, 17644.
17. Bantreil, X.; Nolan, S. P. *Nat. Protoc.* **2011**, 6, 69.
18. Matsubara, K.; Miyazaki, S.; Koga, Y.; Nibu, Y.; Hashimura, T.; Matsumoto, T. *Organometallics* **2008**, 27, 6020.
19. Jang, H.-Y.; Krische, M. J. *J. Am. Chem. Soc.*, **2004**, 126, 7875.
20. Anker, R. M.; Cook, A. H. *J. Chem. Soc.* **1941**, 323.
21. Montgomery, J.; Savchenko, A. V. *J. Am. Chem. Soc.*, **1996**, 118, 2099.
22. Krasovskiy, A.; Knochel, P. *Synthesis-Stuttgart* **2006**, 890.
23. Weiner, B.; Baeza, A.; Jerphagnon, T.; Feringa, B. L. *J. Am. Chem. Soc.*, **2009**, 131, 9473.
24. Xia, J.-B.; Liu, W.-B.; Wang, T.-M.; You, S.-L. *Chem. Eur. J.*, **2010**, 16, 6442.
25. Kim, S.; Chung, Y. K. *Org. Lett.*, **2014**, 16, 4352.
26. Zhang, Q.; Xu, W.; Lu, X. *J. Org. Chem.*, **2005**, 70, 1505.

TOC

